Jazz Pharmaceuticals (JAZZ) Fundamental Analysis: Revenue, Earnings & Valuation

5.01 / 10

Netural

Fundamental health is mixed (5.0/10). Strengths include strong inventory turnover, low cost‑of‑sales ratio and high PB‑ROE weight, while income‑tax ratio and receivables turnover lag. Overall fund‑based score is 5.01, with Asset‑MV and Revenue‑MV contributing positively.

Analysis Checks(6/10)

Revenue-MV

Value0.15

Score2/3

Weight29.92%

1M Return6.87%

Total operating revenue (YoY growth rate %)

Value4.88

Score1/3

Weight-4.30%

1M Return-1.40%

Inventory turnover ratio

Value1.12

Score2/3

Weight-2.22%

1M Return-0.66%

Accounts receivable turnover ratio

Value5.52

Score1/3

Weight-4.99%

1M Return-1.57%

PB-ROE

Value-0.18

Score3/3

Weight51.05%

1M Return12.56%

Income tax / Total profit (%)

Value43.34

Score0/3

Weight-4.51%

1M Return-1.54%

Fixed assets turnover ratio

Value22.87

Score3/3

Weight2.64%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.24%

1M Return-0.73%

Cost of sales ratio (%)

Value11.79

Score3/3

Weight2.79%

1M Return0.79%

Asset-MV

Value-0.55

Score1/3

Weight31.86%

1M Return7.28%

Is JAZZ fundamentally strong?

JAZZ scores 5.01/10 on fundamentals and holds a Fair valuation at present. Backed by its -8.47% ROE, -8.35% net margin, -32.68 P/E ratio, 2.70 P/B ratio, and -164.46% earnings growth, these metrics solidify its Netural investment rating.